Free flavan-3-ol aglycone (2R,3S stereochemistry) — the (+)-enantiomer. Minor component of most flavan-3-ol sources compared with its stereoisomer (−)-epicatechin. Absorbed at the small-intestine enterocyte and extensively glucuronidated / sulfated / methylated (via COMT) before entering portal circulation; free catechin in plasma is <3% of total SRC conjugates. Carbohydrate co-ingestion boosts AUC ~2× (Schramm 2003); dairy protein reduces it. Shares antioxidant, mild eNOS-upregulating, and anti-inflammatory effects with epicatechin.
Half-Life & Elimination Curve (PO: 2h)
Plasma (PO)t½ Decay (2h)
0×t½0h100%(0.562 mg/L)
1×t½2h50%(0.281 mg/L)
2×t½4h25%(0.14 mg/L)
3×t½6h12.5%(70.2 µg/L)
4×t½8h6.3%(35.1 µg/L)
5×t½10h3.1%(17.6 µg/L)
Elimination t½2h (PO)
Rate Constant (ke)0.347 h⁻¹
Time to Peak (Tmax)2.39h
Est. Peak (Cmax)0.562 mg/L
Clearance (CL)12.1 L/h
97% Washout (5×t½)10h
Dosing Guidelines
Oral (PO): Typical 300 mg (Range: 200–500 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 15% · Volume of Distribution (Vd): 35 L · Absorption (ka): 0.5 h⁻¹ (t½ka ≈ 1.39h) [PMID 12798412]